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Extracellular proteolysis by the plasminogen/plasmin (Plg/plasmin) system and MMPs is required for tissue 
injury in autoimmune and inflammatory diseases. We demonstrate that a Plg cascade synergizes with MMP-9/ 
gelatinase B in vivo during dermal-epidermal separation in an experimental model of bullous pemphigoid 
(BP), an autoimmune disease. BP was induced in mice by antibodies to the hemidesmosomal antigen BP180. 
Mice deficient in MMP-9 were resistant to experimental BP, while mice deficient in Plg and both tissue Plg 
activator (tPA) and urokinase Plg activator (uPA) showed delayed and less intense blister formation induced 
by antibodies to BP180. Plg-deficient mice reconstituted locally with Plg or the active form of MMP-9 
(actMMP-9), but not the proenzyme form of MMP-9 (proMMP-9), developed BP. In contrast, proMMP-9 or 
actMMP-9, but not Plg, reconstituted susceptibility of MMP-9–deficient mice to the skin disease. In addition, 
MMP-3–deficient mice injected with pathogenic IgG developed the same degree of BP and expressed levels of 
actMMP-9 in the skin similar to those of WT controls. Thus, the Plg/plasmin system is epistatic to MMP-9 
activation and subsequent dermal-epidermal separation in BP.
Introduction
Extracellular proteolysis is critical for development, tissue repair, 
and progression of diseases in vivo (1). These processes are strictly 
confined because cascades of proteinases activate the zymogen 
forms of the proteinases. One of the best understood of these cas-
cades is the fibrinolytic system of serine proteinases (2). The abun-
dant zymogen plasminogen (Plg) is proteolytically converted into 
the active serine proteinase plasmin by either of 2 Plg activators, 
the tissue Plg activator (tPA) or the urokinase Plg activator (uPA), 
that then degrades fibrin. MMPs are also synthesized as zymogens 
that must be activated for proteolysis. The Plg/plasmin cascade 
was proposed as a physiological regulatory system for activating 
MMPs more than 25 years ago (3). Subsequently, MMPs and serine 
and cysteine proteinases have been shown to activate latent forms 
of various members of the MMP family in vitro (4). However, little 
is known about the regulation of MMP activation in vivo.
Bullous pemphigoid (BP) is an autoimmune inflammatory 
skin disease initiated by in vivo deposition of autoantibodies and 
complement components at the basement membrane zone (5). BP 
autoantibodies recognize 2 major hemidesmosomal components, 
the 230-kDa intracellular protein BP230 (BPAG1) (6, 7) and the 
180-kDa transmembrane protein BP180 (BPAG2, or type XVII 
collagen) (8, 9). The separation of the epidermis from the dermis 
occurs within the lamina lucida of the basement membrane and is 
accompanied by an extensive inflammatory infiltrate and destruc-
tion of hemidesmosomal and extracellular matrix components (10, 
11). Proteinases released from infiltrating inflammatory cells have 
been implicated in the subepidermal blistering of BP (12). High 
levels of proteolytic enzymes, including neutrophil elastase (NE), 
cathepsin G, Plg activators (PAs), plasmin, MMP-2/gelatinase A, 
and MMP-9, have been detected in BP blister fluids and lesional/
perilesional sites (13–20). NE and MMP-9 degrade the recombi-
nant BP180 and are required for dermal-epidermal separation 
induced by BP autoantibodies in a skin culture model (20–22).
In the present study, we used an IgG passive transfer mouse 
model of BP that mimics the key features of human BP (23). In our 
model, subepidermal blistering triggered by anti-murine BP180 
(anti-mBP180) IgG depends on complement activation, mast cell 
(MC) degranulation, and polymorphonuclear leukocyte (PMN) 
infiltration (24–26). Mice with targeted null mutations in either 
MMP-9 (27) or NE (28) are resistant to experimental BP. MMP-9 
regulates NE activity by inactivating α1-proteinase inhibitor 
(α1-PI), and unchecked NE degrades BP180 and other extracellular 
matrix components at the dermal-epidermal junction, resulting in 
BP lesions (29). In this report, we determine functional interac-
tions between MMP-9 and the Plg/plasmin system in subepider-
mal blistering in experimental BP.
Results
Mice deficient in Plg or both tPA and uPA are resistant to experimental BP. 
C57BL/6J mice, tPA-deficient mice, and uPA-deficient mice (n = 9 
for each group), injected with rabbit anti-mBP180 antibodies but 
not control rabbit IgG, developed typical BP skin lesions clinically 
and histologically 12 hours after injection (Figure 1, A, B, E, and 
F; and Table 1). In contrast, mice deficient in both tPA and uPA 
(tuPA–/–) or Plg (Plg–/–) injected with the same dose of pathogenic 
IgG showed no skin abnormality (Figure 1, G and H). Plasmin 
chromogenic assays showed significantly elevated plasmin activ-
ity in the lesional skin whereas Plg–/– and tuPA–/– mice exhibited 
only background levels of plasmin activity in the nonlesional skin 
(Figure 1I). As expected (23, 25), infiltrating neutrophils were pres-
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ent in the upper dermis at the lesional/perilesional site and within 
the blister cavity as shown by histology (Figure 1B, inset).
At 4 hours after IgG injection, all mice had similar numbers of infil-
trating neutrophils in the skin, quantified by the myeloperoxidase 
(MPO) assay, indicating that the absence of plasmin activity did 
not interfere with the early stages of neutrophil migration from the 
circulation into the tissue inflammatory site (Figure 1J). However, 
by 12 hours after injection, neutrophil infiltration was significant-
ly higher in the diseased mice (WT, tPA–/–, and uPA–/–) than in the 
Plg–/– and tuPA–/– unaffected mice (n = 9 for each group; Figure 1J). 
These results demonstrate that the Plg/plasmin system directly con-
tributes to subepidermal blistering in experimental BP.
Plasmin acts upstream of MMP-9. Our previous data show that 
MMP-9 is required for subepidermal blistering (27). Since plasmin 
is also directly involved in disease development, we next assessed 
the relationship between MMP-9 and plasmin in experimental 
BP by injecting Plg–/– and MMP-9–/– mice with pathogenic anti-
mBP180 IgG, then 1 hour later reconstituting 
locally with Plg, the proenzyme form of MMP-9 
(proMMP-9), or the active form of MMP-9 (act-
MMP-9) (n = 9 for each group). Plg–/– mice reconsti-
tuted with Plg or actMMP-9, but not proMMP-9, 
developed BP lesions by 12 hours after IgG injec-
tion (Figure 2, A–D). MMP-9–/– mice reconstituted 
with actMMP-9 or proMMP-9, but not Plg, also 
developed subepidermal blisters (Figure 2, E–H). 
These results demonstrate that actMMP-9 can 
compensate for the deficiency of Plg in BP devel-
opment while Plg cannot compensate for the defi-
ciency of MMP-9. We conclude that plasmin acts 
upstream of MMP-9.
Since plasmin can activate MMP-3 and MMP-3 
can activate proMMP-9 in vitro (30–33), we then 
sought to determine whether MMP-3 directly 
activates MMP-9. MMP-3 null mice (n = 8), when 
injected with pathogenic IgG, developed the same 
degree of BP disease as WT control mice (Table 
1), and similar levels of MMP activity were found 
in the lesional skin of both groups of mice (Fig-
ure 2I). Furthermore, like WT mice, MMP-3 null 
mice (n = 8) pretreated with the plasmin inhibitor 
α2-antiplasmin (α2-AP) became resistant to BP 
with minimal levels of plasmin activity in the IgG 
injection site (Table 1). Taken together, our data 
indicate that plasmin activates MMP-9 indepen-
dently of MMP-3.
Lack of plasmin activity does not affect MC activa-
tion. Subepidermal blistering triggered by anti-
BP180 antibodies depends on MC degranulation, 
which peaks at 2 hours after pathogenic IgG 
injection (26). To rule out the possibility that 
resistance of plasmin-deficient mice to experi-
mental BP is due to the lack of MC activation, we 
quantified MC degranulation in the pathogenic 
IgG-injected Plg–/– and tuPA–/– mice. As shown 
in Figure 3, 2 hours after pathogenic IgG injec-
tion, these plasmin-deficient mice had levels of 
MC degranulation similar to those of WT mice 
and mice deficient in tPA or uPA (n = 6). These 
results demonstrate that MC activation is nor-
mal in plasmin activity–deficient mice and occurs upstream of 
plasmin generation and subsequent MMP-9 activation.
MMP-9 activation is plasmin dependent. Both proMMP-9 and act-
MMP-9 were present in the lesional skin of WT mice as shown by 
gelatin zymography (Figure 4A, lanes 1 and 3). In contrast, the non-
lesional skin extracts of Plg–/– mice and tuPA–/– mice showed only 
proMMP-9 (Figure 4A, lanes 2 and 4). Plasmin converts proMMP-9 
released from pathogenic anti-mBP180 IgG–stimulated neutrophils 
to actMMP-9 in a cell system as assayed by gelatin zymography and 
the MMP colorimetric assay (Figure 4B, lane 1 and bar 1). In addi-
tion, plasmin activates recombinant mouse proMMP-9 in vitro (Fig-
ure 4C, lane 2 and bar 2). These results reveal the plasmin-dependent 
proteolytic activation of MMP-9 during lesion formation.
Inhibition of plasmin activity blocks blister formation in experimental 
BP. If plasmin directly contributes to MMP-9 activation, which 
in turn leads to subepidermal blistering in experimental BP, then 
blocking plasmin activity should inhibit MMP-9 activation and 
Figure 1
The Plg/plasmin system is required for experimental BP. WT mice and mice deficient 
in different components of the Plg/plasmin system were injected i.d. with pathogenic 
anti-mBP180 IgG (R530) or control IgG and examined 12 hours later. (A–H) WT (A 
and B), tPA–/– (E), and uPA–/– (F), but not tuPA–/– (G) or Plg–/– (H) mice injected with 
pathogenic IgG developed subepidermal blisters. WT injected with control IgG showed 
no disease (C and D). Arrows indicate sites of basal keratinocytes. E, epidermis; D, 
dermis; V, blister vesicle. Magnification, ×200. Higher magnifications of H&E staining 
sections demonstrate infiltrating neutrophils in the dermis (insets). Arrowheads indicate 
neutrophils. Magnification, ×920. (I) Plasmin chromogenic assay showed significantly 
higher levels of plasmin activity in the lesional skin of WT (bar 1), tPA–/– (bar 3), and 
uPA–/– (bar 4) mice as compared with the nonlesional skin of control (bar 2), tuPA–/– 
(bar 5), and Plg–/– (bar 6) mice. Data shown are the mean ± SEM. n = 9 for each group; 
*P < 0.001 versus WT. (J) MPO activity assay at 12 hours after injection (black bars) 
showed significantly higher levels of PMN recruitment in the lesional skin of WT (bar 7), 
tPA–/– (bar 9), and uPA–/– (bar 10) mice as compared with tuPA–/– (bar 11) and Plg–/– (bar 
12) mice. At 4 hours after injection (gray bars), all mice had similar numbers of infiltrating 
neutrophils. n = 9 for each group; *P < 0.001 versus WT.
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the disease phenotype. Accordingly, we injected neonatal WT mice 
with pathogenic anti-mBP180 IgG and 90 minutes later injected 
them at the same site with the plasmin inhibitor α2-AP. Control 
mice, which received anti-mBP180 IgG followed by PBS, developed 
intense blisters 12 hours after the antibody administration (n = 9; 
Figure 5A). Similarly, mice coinjected with pathogenic antibody 
and α1-antichymotrypsin (α1-AC) (Figure 5A), an inhibitor of the 
neutrophil cathepsin G, or coinjected with pathogenic antibody 
plus heat-inactivated α2-AP also developed subepidermal blisters 
(n = 9; data not shown). In contrast, mice that were treated with 
pathogenic IgG followed by α2-AP did not develop skin lesions 
(n = 9; Figure 5A). Blocking plasmin activity by α2-AP reduced 
PMN influx, which is a measure of disease severity, by 59% as deter-
mined by MPO activity (Figure 5A). Plasmin activity in the skin 
of mice treated with α2-AP was significantly inhibited compared 
with that in control mice or mice treated with α1-AC (Figure 5B). 
In addition, the nonlesional skin extracts of mice treated with 
α2-AP showed a minimal level of MMP-9 activation (Figure 5C, 
lane 2 and bar 2) while high levels of MMP-9 activation were pres-
ent in the lesional skin of control mice and mice treated with α1-AC 
(Figure 5C, lanes 1 and 3, bars 1 and 3). These data further estab-
lish that MMP-9 activation in vivo depends on plasmin activity.
Local reconstitution of neutrophils restores subepidermal blistering in 
Plg-deficient mice. The function of actMMP-9 in experimental BP is 
to upregulate NE activity by inactivating α1-PI (29). If the major 
function of plasmin is to activate MMP-9, then plasmin-deficient 
mice should have lower levels of NE and higher levels of α1-PI in 
the pathogenic IgG-injected skin site, and local reconstitution of 
neutrophils should bypass the requirement of plasmin activity 
and restore BP disease in plasmin-deficient mice. Our next set of 
experiments showed that this is the case. WT, MMP-9–/–, Plg–/–, and 
tuPA–/– mice (n = 9 for each group) were injected with pathogenic 
IgG. At 4 hours and 12 hours after injection, levels of plasmin, 
MMP-9, NE, and α1-PI in the skin of these mice were quantified. 
Table 1
The relationship between Plg/plasmin system and MMP-9  
in experimental BP
Genotype  Treatment No. of  Mean disease 
of host mice  mice activity score
+/+ – 49 2.83 ± 0.05
 + α1-AC 9 2.78 ± 0.12
 + Active α2-AP 9 0.06 ± 0.06
 + Inactive α2-AP 9 2.78 ± 0.12
Plg–/– – 21 0.00 ± 0.00
 + Plg 9 2.78 ± 0.15
 + proMMP-9 9 0.00 ± 0.00
 + actMMP-9 9 2.72 ± 0.15
 + 5 × 105 PMN 6 3.00 ± 0.00
tPA–/– – 9 2.67 ± 0.14
uPA–/– – 9 2.67 ± 0.12
tuPA–/– – 9 0.11 ± 0.07
MMP-9–/– – 9 0.00 ± 0.00
 + Plg 12 0.00 ± 0.00
 + proMMP-9 9 2.61 ± 0.14
 + actMMP-9 9 2.94 ± 0.06
MMP-3–/– – 8 2.81 ± 0.09
 + Active α2-AP 8 0.13 ± 0.08
Neonatal +/+, Plg–/–, tPA–/–, uPA–/–, tuPA–/–, MMP-9–/–, and MMP-3–/–  
mice were injected i.d. with pathogenic anti-mBP180 IgG (2.64 mg/g 
body weight). Purified mouse Plg (5 μg/g body weight), proMMP-9 (2.5 
μg/g body weight), or actMMP-9 (2.5 μg/g body weight) was given i.d. 
1 hour after IgG injection. Purified α1-AC (25 μg/g body weight), active 
α2-AP (25 μg/g body weight), heat-inactivated α2-AP (25 μg/g body 
weight), or neutrophils (5 × 105 cells/50 μl in PBS) were given i.d. 90 
minutes after IgG injection. Injected animals were examined clinically 12 
hours after IgG injection, and disease activity was scored and averaged 
in each group (mean disease score ± SEM). There was a significant  
difference in clinical disease scores between mice with blisters and 
mice without blisters (P < 0.01). 
Figure 2
Plasmin generation is upstream of MMP-9 activation. (A–D) actMMP-9 
reconstitution restores BP in Plg–/– mice. (A) Pathogenic anti-mBP180 
IgG (R530, i.d. injection, 2.64 mg/g body weight) induced subepidermal 
blistering in neonatal Plg–/– mice reconstituted with mouse Plg (5 μg/g 
body weight) (B) and actMMP-9 (2.5 μg/g body weight) (D) but not 
proMMP-9 (2.5 μg/g body weight) (C) and PBS control (A). (E–H) Plg 
reconstitution failed to restore BP in MMP-9–/– mice. Pathogenic anti-
mBP180 IgG (i.d. injection, 2.64 mg/g body weight) induced subepider-
mal blistering in neonatal MMP-9–/– mice reconstituted with the same 
amount of proMMP-9 (G) and actMMP-9 (H) but not mouse Plg (F) or 
PBS control (E). Magnification, ×200. (I) Like +/+ mice, MMP-3–/– mice 
developed extensive clinical and histological blisters (Table 1) and com-
patible levels of MMP activity at 12-, 24-, 48-, and 72-hour time points 
as determined by MMP colorimetric assay (mean ± SEM).
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At the 4-hour time point, there was no significant difference in the 
levels of plasmin activity between MMP-9+/+ and MMP-9–/– mice; 
their plasmin levels, however, were significantly higher than those 
of Plg–/– and tuPA–/– mice (Figure 6A). At the 12-hour time point, 
increased levels of plasmin activity were seen in the lesional skin of 
normal control (+/+) mice as compared with the nonlesional skin 
of MMP-9–/–, Plg–/–, and tuPA–/– mice. These data reveal an ampli-
fication step for local plasmin activity during blistering, a finding 
similar to that observed for NE in experimental BP (29). At both 
4 hours and 12 hours after injection, skin protein extracts of WT 
mice showed significantly higher levels of MMP activity (Figure 
6B) and NE activity (Figure 6C) and lower levels of α1-PI activity 
(Figure 6D) than those of deficient mice. Levels of MMP-9, NE, 
and α1-PI activities were compatible among these deficient mice. 
Plg–/– mice reconstituted with 5 × 105 neutrophils from WT, Plg–/–, 
or MMP-9–/– mice (n = 6 for each group) developed subepidermal 
blisters 12 hours after pathogenic IgG injection (Figure 6, E–H). 
These results clearly demonstrate that neutrophils are normal in 
Plg deficiency. Since local injection of Plg–/– neutrophils restored 
BP in Plg–/– mice, we conclude that the major role for plasmin is 
MMP-9 activation but not direct tissue injury.
To rule out the possibility that plasmin directly participates in 
the degradation of basement membrane proteins in the later stages 
during the BP blistering, we injected MMP-9–deficient mice with 
pathogenic IgG and examined them at 24, 48, and 72 hours after 
injection. All mice showed no skin lesions, which further confirms 
and extends our previous observations (27, 29).
A plasmin-independent pathway can activate MMP-9 late in the evolution 
of experimental BP. Our previous studies have shown that the cell 
population and the tissue microenvironment changes dramatically 
over the first 12 hours after injection of pathogenic IgG and con-
tinues to evolve over the next few days (25, 26, 29). The experiments 
described above indicate that plasmin plays a critical role in MMP-9 
activation during the early stages of subepidermal blistering. We 
then examined WT, Plg–/–, and tuPA–/– mice (n = 6) that were injected 
Figure 3
MC activation in Plg- and tuPA-deficient mice. WT, Plg–/–, and tuPA–/– 
mice were injected i.d. with pathogenic IgG (R530; 2.64 mg/g body 
weight). At 2 hours after injection, when MC degranulation reached the 
peak level, skin sections were stained with toluidine blue solution. (A–D) 
Toluidine blue staining showed similar degrees of MC degranulation 
in pathogenic IgG-injected WT and deficient mice. (E) The MCs in the 
dermis were counted and classified as degranulated (more than 10% 
of the granules exhibiting fusion or discharge) or normal (see Meth-
ods). There was no significant difference in MC degranulation among 
these mice (mean ± SEM). Arrows indicate MCs.
Figure 4
MMP-9 activation by plasmin in vivo and in vitro. (A) To identify MMP-9 
activation in the lesional skin of experimental BP, neonatal Plg+/+, 
Plg–/–, tuPA+/+, and tuPA–/– mice were injected i.d. with pathogenic 
anti-mBP180 IgG. Skin samples were obtained at 4 hours after IgG 
injection, and protein extracts (30 μg/lane) were analyzed by gelatin 
zymography. Both proMMP-9 and actMMP-9 were seen in lesional 
skin samples of IgG-injected +/+ mice (lanes 1 and 3). In contrast, 
no actMMP-9 was found in skin samples of pathogenic IgG-injected 
Plg–/– (lane 2) and tuPA (lane 4) mice. (B) To show MMP-9 activation in 
a cell system, mouse neutrophils (mPMN; 1 × 105) were stimulated by 
pathogenic anti-mBP180 IgG (5 μg/ml) plus mBP180 antigen (5 μg/ml) 
at 37°C for 1 hour. The supernatant was then incubated with plasmin 
(2 μg/ml) at 37°C for 16 hours. proMMP-9 released by neutrophils was 
activated by plasmin as shown by gelatin zymography (lane 1) and 
MMP colorimetric assay (bar 1). n = 6; *P < 0.001. (C) To show MMP-9 
activation in vitro, the recombinant mouse proMMP-9 (1 μg) was 
incubated with plasmin (1 μg) in 100 μl of reaction buffer at 37°C for 
6 hours and assayed by gelatin zymography and MMP colorimetric 
assay. Plasmin converted proMMP-9 to actMMP-9 (lane 2 and bar 2), 
and the activation was blocked by the plasmin inhibitor α2-AP (lane 3 
and bar 3). n = 6; *P < 0.001.
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 115   Number 4   April 2005 883
with pathogenic IgG at 12, 24, 48, and 72 hours. As expected, WT 
mice developed extensive BP blisters at all time points (Figure 7A). 
Plg–/– mice showed no skin lesions at 12 hours, but developed pathol-
ogy later, showing 0.5+, 1+ and 1.75+ disease scores at 24 hours, 48 
hours, and 72 hours, respectively. Similarly, tuPA–/– mice developed 
no skin blisters at 12 hours, 1+ disease score at 24 hours, and 2+ dis-
ease score at 48 hours. We were not able to examine the later disease 
scores in tuPA–/– mice as all had died by 72 hours. A colorimetric 
assay revealed that MMP activity increased in the lesional skin of 
these plasmin-deficient mice after 12 hours (Figure 7B). These data 
suggest that in experimental BP, MMP-9 is activated initially by 
plasmin and later in concert with other activating enzyme(s).
Discussion
Our study shows that the Plg/plasmin system plays a critical role 
early in the evolution of subepidermal blistering in experimental 
BP by mediating the physiologic activation of MMP-9. Several lines 
of evidence support a role for plasmin: (a) the lesional/perilesional 
skin of experimental BP mice exhibited abnormally high levels of 
plasmin; (b) Plg–/– and tuPA–/– mice were resistant to experimen-
tal BP; (c) Plg–/– mice reconstituted with Plg became susceptible 
to experimental BP; (d) plasmin inhibitors (α2-AP) blocked sub-
epidermal blistering in experimental BP; (e) in the early stages 
of blistering, no actMMP-9 was detected without plasmin activ-
ity, though later on, plasmin, in concert with other unidentified 
mechanism(s), caused MMP-9 activation and subsequent dermal-
epidermal separation (Figure 8).
The PA/plasmin system plays a key role in the proteolytic clear-
ance of extracellular matrix components. Using Plg–/– mice, it 
has been shown that the Plg/plasmin cascade is directly involved 
in inflammation, infection, tissue injury/wound healing, can-
cer growth and metastasis, and antibody-mediated tissue injury 
(33–50). In these physiologic and pathologic conditions, the Plg/
plasmin system itself is implicated in matrix degradation. Like 
other MMPs, MMP-9 is secreted in an inactive form and is acti-
vated extracellularly. proMMP-9 can be activated by plasmin, uPA 
(4, 51–54), chymase (55), tissue kallikrein (56), and other active 
MMPs (31, 57–60). To our surprise, we found that the major func-
tion of plasmin early in BP development is activating MMP-9, 
since MMP-9–/– mice reconstituted with Plg are still resistant to BP. 
This notion is further sustained by the striking similarity between 
Plg–/– and tuPA–/– mice: mice lacking Plg or PAs show very similar 
reduction in BP disease severity and almost identical pathology. 
These findings also strongly suggest that the failure to develop 
subepidermal blisters in Plg–/– and tuPA–/– mice is due to a failure 
of local plasmin generation rather than some independent func-
tional property of PA or Plg. MMP-9 can also be activated by reac-
tive oxygen species produced by activated neutrophils (61). This 
pathway may play an important role in experimental BP and is 
currently under investigation in our laboratory.
Purified plasmin can directly activate purified mouse proMMP-9 
in vitro; however, as is always the case for genetic epistasis, we can-
not rule out that an intermediate enzyme is activated by plasmin 
and in turn activates MMP-9. It has been hypothesized that plasmin 
activates MMP-9 indirectly through activation of MMP-3, since in 
vitro plasmin activates MMP-3, which activates MMP-9, at least in 
human enzymes (30–33). In the present study, however, MMP-3–
deficient mice did not show impaired MMP-9 activation and were 
susceptible to experimental BP. These data exclude MMP-3 as an in 
vivo activator of MMP-9 in the BP model as has been reported for a 
vascular injury model (52).
Our experimental BP model has been very valuable in dissect-
ing the sequence of events that lead to blister formation (29). Our 
present study adds a new dimension to the understanding of the 
early stages of disease development, showing that at 12 hours after 
injection, plasmin is rate limiting for MMP-9 activation and sub-
sequent blistering. At later time points (24–72 hours), however, 
pathogenic IgG still induces BP in Plg–/– and tuPA–/– mice, which 
indicates that another pathway independent of plasmin is able 
to overcome this defect eventually and produce the activation of 
MMP-9 and lesion formation. Further investigation should iden-
tify later events in the evolution of experimental BP.
Figure 5
Blocking plasmin activity abolishes experimental BP. To demonstrate 
that α2-AP treatment blocks plasmin activity and subsequent MMP-9 
activation and blistering, WT mice were injected i.d. with pathogenic 
anti-mBP180 IgG (2.64 mg/g body weight) followed by local adminis-
tration of PBS, the plasmin inhibitor α2-AP, or the neutrophil cathepsin 
G inhibitor α1-AC. Mice were examined at 12 hours after IgG injec-
tion. (A) Pathogenic anti-mBP180 IgG induced high levels of neutro-
phil infiltration and subepidermal blisters in +/+ mice (bar 1) and mice 
treated with α1-AC (bar 3) but not in mice treated with α2-AP (bar 2). 
n = 9; *P < 0.01. (B) Plasmin activity assay showed a significant 
reduction of tissue plasmin activity in the α2-AP–treated mice (bar 2) 
as compared with that in the PBS-treated (bar 1) and α1-AC–treated 
mice (bar 3). n = 8 for each group; **P < 0.001. (C) Zymography assay 
detected an actMMP-9 band in the skin of mice treated with PBS (lane 
1) and α1-AC (lane 3) but not in the skin of mice treated with α2-AP 
(lane 2). MMP colorimetric assay revealed a significant reduction of 
active MMP levels in the skin samples of α2-AP–treated mice (bar 2) 
as compared with those in the lesional skin samples of PBS- (bar 1) 
and α1-AC–treated mice (bar 3). n = 8; #P < 0.05.
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Our current data do not rule out the possibility that plasmin 
also degrades basement membrane proteins, in concert with other 
proteolytic enzymes, after the initial tissue injury. This functional 
overlap between MMPs and plasmin has been observed during 
wound healing (62).
We have previously shown that NE and MMP-9 generate and 
maintain chemoattractant levels in the BP lesions in the second 
phase of disease development, between 6 and 12 hours after injec-
tion (27). The PA/plasmin system has also been implicated in cell 
migration during some physiologic and pathologic processes. 
However, we found no obvious impairment in recruitment of 
neutrophils in the early stages of subepidermal blistering in mice 
deficient in Plg and tuPA. Initial recruitment of neutrophils at 4 
hours after injection was comparable in Plg–/–, tuPA–/–, and WT 
mice. At 12 hours after injection, when BP is fully developed, 
further recruitment of neutrophils is severely impaired in these 
deficient mice. Thus, the PA/plasmin system may contribute to 
neutrophil recruitment by activating MMP-9.
Does the Plg/plasmin system have any relevance to human BP? 
The Plg/plasmin system has been implicated in the development 
of BP. Elevated levels of plasmin and PAs are found in the blister 
fluid and lesional skin of BP patients (17–19, 63, 64).
Due to its abundance, widespread distribution, and broad 
substrate specificity, plasmin has been implicated in a variety 
of pathologies, such as thrombosis, atherosclerosis, tumor cell 
invasion and metastasis, and some autoimmune and inflam-
matory disorders (1). Although many substrates for plasmin 
have been identified in vitro, substrates in these pathologic 
conditions remain largely unknown. The present study points 
to MMP-9 as the critical substrate for plasmin in subepider-
mal blistering. Activated MMP-9 and other proteolytic enzymes 
damage basement membrane proteins, causing BP. Elucida-
tion of the role of the Plg/plasmin system in BP gives us new 
insights into the immunopathogenesis of autoimmune diseases 
and suggests that this proteolytic system is a potential target 
for therapeutic intervention.
Figure 6
Functional relationship between plasmin, MMP-9, NE, and α1-PI in 
experimental BP. +/+, MMP-9–/–, Plg–/–, and tuPA–/– mice (n = 6) were 
injected with anti-mBP180 IgG and examined 4 hours and 12 hours 
later. (A) Plasmin activity assay showed similar levels of tissue plasmin 
activity in +/+ and MMP-9–/– mice at 4 hours but significantly higher 
levels of tissue plasmin activity in the lesional skin of +/+ (bar 5) mice 
compared with MMP-9–/– (bar 6), Plg–/– (bar 7), and tuPA–/– (bar 8) mice 
at 12 hours. (B) MMP colorimetric assay revealed increased levels of 
MMP activity in lesional skin of +/+ mice (bars 1 and 5) as compared 
with those in nonlesional skin of MMP-9–/– (bars 2 and 6), Plg–/– (bars 
3 and 7), and tuPA–/– (bars 4 and 8) mice. (C) NE activity was signifi-
cantly higher in the lesional skin of +/+ mice (bars 1 and 5) relative to 
MMP-9–/– (bars 2 and 6), Plg–/– (bars 3 and 7), and tuPA–/– (bars 4 and 
8) mice. (D) NE inhibition assay showed a significantly reduced level of 
α1-PI in the lesional skin of +/+ mice (bars 1 and 5) as compared with 
the skin of MMP-9–/– (bars 2 and 6), Plg–/– (bars 3 and 7), and tuPA–/– 
(bars 4 and 8) mice. *P < 0.05 and **P < 0.001 for paired samples. 
(E–H) Plg–/– mice, when reconstituted locally with 5 × 105 neutrophils 
from +/+ (F), Plg–/– (G), or MMP-9–/– (H) mice, developed BP blisters 
12 hours after pathogenic IgG injection. n = 6.
Figure 7
Plasmin-independent activation of MMP-9 in experimen-
tal BP. +/+, Plg–/–, and tuPA–/– mice (n = 6) were injected 
i.d. with pathogenic IgG (2.64 mg/g body weight) and 
examined at 12, 24, 48, and 72 hours after injection. Note 
that all tuPA–/– mice died by 72 hours. (A) At 12 hours, 
only +/+ mice developed clinical and histological blisters. 
After 24 hours, all mice showed clinical blistering, but dis-
ease severity (mean disease score ± SEM) in Plg–/– and 
tuPA–/– mice was significantly lower than in +/+ mice. (B) 
MMP colorimetric assay showed a significantly higher 
MMP activity in +/+ mice than in Plg–/– and tuPA–/– mice 
at all time points. *P < 0.05; **P < 0.001.
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Methods
Reagents. Purified murine MMP-9 was obtained from Triple Point Biolog-
ics Inc. The proenzyme of MMP-9 was activated by incubation at 37°C 
for 4 hours with aminophenylmercuric acetate at 1 mM, and the incuba-
tion mixture was then dialyzed against PBS at 4°C to remove aminophen-
ylmercuric acetate. Purified murine Plg was purchased from American 
Diagnostica Inc. Human plasmin, human α1-AC, human α1-PI, human 
α2-AP, human NE, and human neutrophil MPO were from Athens 
Research and Technology Inc.
Animals. C57BL/6J, Plg–/–, tPA–/–, and uPA–/– mice were purchased from 
the Jackson Laboratory. MMP-3–/– mice were obtained from Taconic. 
MMP-9–/– and matched normal control (+/+) mice were generated as pre-
viously described (65). Mice deficient in both tPA and uPA (tuPA–/–) were 
generated by crossing tPA–/– and uPA–/– mice followed by interbreeding of the 
heterozygous offspring. The identity of tuPA deficiency was confirmed by 
casein zymography (see below). Breeding pairs of these mice were maintained 
at the Medical College of Wisconsin Animal Resource Center and the Divi-
sion of Laboratory Animal Medicine at the University of North Carolina at 
Chapel Hill. Neonatal mice, 24 to 48 hours old, weighing 1.4–2.0 g, were used 
for passive transfer experiments. All animal experiments were approved by 
the Animal Studies Committee of the University of North Carolina at Cha-
pel Hill School of Medicine and were in accordance with NIH guidelines.
Preparation of pathogenic anti-BP180 antibodies and induction of experimental 
BP. The preparation of recombinant mBP180 and the immunization of 
rabbits were performed as previously described (23). The titers of rabbit 
anti-mBP180 antibodies in the rabbit sera and in the purified IgG fractions 
were assayed by indirect immunofluorescence, using mouse skin cryosec-
tions as substrate (23). The pathogenicity of these IgG preparations was 
tested by passive transfer experiments, as described below.
For induction of experimental BP and clinical evaluation, neonates were 
given 1 intradermal (i.d.) injection (50 μl each, 2.64 mg/g body weight) of 
a sterile solution of IgG in PBS, as described elsewhere (23, 24). The skin 
of neonatal mice from the test and control groups was examined 12–72 
hours after the IgG injections. The activity of cutaneous disease was scored 
as follows: 0, no detectable skin disease; 1+, mild erythematous reaction 
with no evidence of “epidermal detachment” (epidermal detachment was 
elicited by gentle friction of the skin which, when positive, produced fine, 
persistent wrinkling of the epidermis); 2+, intense erythema and epidermal 
detachment involving 10–50% of the epidermis at the injection site; and 3+, 
intense erythema with frank epidermal detachment involving more than 
50% of the epidermis at the injection site. Disease activity in each group of 
mice was expressed as mean disease activity score (see Table 1).
Injection of Plg, MMP-9, α1-AC, and α2-AP. Neonatal mice were injected 
i.d. with 50 μl of human α1-AC (25 μg/g body weight), human α2-AP (25 
μg/g body weight), mouse Plg (5 μg/g body weight), or mouse MMP-9 (2.5 
μg/g body weight) prior to injection of pathogenic IgG (2.64 mg/g body 
weight). Skin was examined at different time points for clinical lesions. 
IgG injection sites were excised and extracted for analysis of neutrophil 
infiltration and enzyme activities. Endotoxin levels in Plg, MMP-9, α1-AC, 
and α2-AP preparations were minimal: mice injected with these reagents 
alone showed no inflammatory response in the skin as determined by MPO 
enzyme activity assay (see below).
MPO, MMP-9, and plasmin assays. For quantification of PMN accumula-
tion in the skin, tissue MPO activity in skin sites of the injected animals 
was assayed as previously described (66), using purified MPO as standard. 
MPO activity in supernatants was measured by the change in OD at 460 
nm resulting from decomposition of H2O2 in the presence of o-dianisidine. 
MPO content was expressed as relative MPO activity (OD460nm reading/
mg protein of the mouse skin injected with pathogenic anti-mBP180 IgG 
minus OD460nm reading/mg protein of the mouse skin injected with control 
IgG). Protein concentrations were determined by the Bio-Rad dye-binding 
assay (Bio-Rad Laboratories), using BSA as a standard.
MMP-9 in protein extracts of skin sections from injected animals and in 
supernatants of stimulated neutrophils was determined by gelatin gel zymog-
raphy, as previously described (27, 67). Levels of active MMPs in the skin pro-
tein extracts were quantified with an MMP colorimetric assay kit following 
manufacturer’s instructions (BIOMOL). Briefly, protein samples were incu-
bated with the MMP colorimetric substrate Ac-PLG[2-mercapto-4-methyl]-
LG-OC2H5 in reaction buffer (final substrate concentration, 100 μM) at 37°C. 
MMP activity in protein extracts was measured by the change in OD at 412 
nm and was expressed as relative MMP activity (OD412nm reading/min/mg 
protein of mouse skin injected with pathogenic IgG minus OD412nm reading/
min/mg protein of mouse skin injected with normal control IgG).
Plasmin activity in skin extracts of mice was measured using the 
chromogenic substrate Val-Leu-Lys-p-nitroanilide (Sigma-Aldrich) (68). 
Skin protein extracts were incubated with 0.6 mM substrate in 50 mM 
Tris-HCl, pH 7.4, and 110 mM NaCl. The absorbance at 405 nm was read. 
Backgrounds due to overlapping activities of other serine proteases were 
determined using skin extracts plus the plasmin inhibitor α2-AP. Plasmin 
activity was expressed as relative plasmin activity (OD405nm/mg protein 
minus OD405nm/mg protein in the presence of α2-AP).
Quantification of NE and α1-PI activities. NE activity in the skin of mice 
was measured using the NE-specific substrate methoxysuccinyl-Ala-Ala-
Pro-Val-p-nitroanalide (Met-O-Suc-Ala-Ala-Pro-Val-pNA; Enzyme Sys-
tems Products) as previously described (28). The tissue NE activity was 
expressed as relative NE activity (OD420nm/min/mg protein). To quantify 
levels of α1-PI activity in the skin, an NE inhibition assay was employed. 
Briefly, purified NE was incubated with different amounts of purified 
α1-PI at 25°C for 5 minutes, and then the NE-specific substrate was added. 
Residual NE activities were measured by reading at 420 nm as above, and 
an NE–inhibition standard curve was generated. The tissue α1-PI activity 
was determined by monitoring the change in absorbance at 420 nm and 
was expressed as relative α1-PI activity (1 – OD420nm/mg protein).
Isolation of PMN, local reconstitution of PMN, and activation of proMMP-9 in cell 
culture. PMNs were isolated from heparinized blood from WT and knock-
out mice by dextran sedimentation followed by separation on a density 
Figure 8
Working model of MMP-9 activation in experimental BP. Experimental 
BP is initiated by pathogenic anti-BP180 and depends on complement 
activation, MC degranulation, and neutrophil infiltration. Infiltrating 
neutrophils (PMNs) upon activation release NE, proMMP-9, and other 
proteinases. In the early stages of blistering, proMMP-9 is mainly acti-
vated by plasmin, which is generated from Plg by tPA and/or uPA. 
Plasmin and other activators of MMP-9 activate proMMP-9. actMMP-9 
cleaves α1-PI to release NE. Unchecked NE degrades BP180 and 
other ECM components, resulting in dermal-epidermal separation.
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gradient (69). PMN purity of the final cell preparation was consistently 
greater than 96% as determined by cell-cytospin and LeukoStat staining 
(Fisher Diagnostics). The viability of the PMNs was greater than 96% as 
determined by trypan blue exclusion. PMNs were kept in PBS with 10 
mM glucose at 4°C before use. For neutrophil reconstitution, neonatal 
mice were injected i.d. with pathogenic IgG and, 90 minutes later, 5 × 105 
neutrophils in 50 μl PBS were injected into the IgG-injection site. For 
MMP-9 activation in cell culture, 1 × 105 purified mouse neutrophils were 
activated with rabbit anti-mBP180 IgG (5 μg/ml) and mBP180 antigen 
(5 μg/ml) for 1 hour at 37°C and then incubated with plasmin (2 μg/ml) at 
37°C for 16 hours. The supernatants were collected and analyzed by gela-
tin zymography and the MMP-9 colorimetric assay described above.
Activation of MMP-9 by plasmin in vitro. Proteolytic activation of MMP-9 
in vitro was performed as previously described (30). Briefly, 1 μg of mouse 
MMP-9 and 1 μg of human plasmin in 100 μl of reaction buffer (5 mM Tris-
HCl, pH 7.5, and 0.1 mM CaCl2) were incubated at 37°C for 6 hours. Levels of 
actMMP-9 were quantified by the MMP colorimetric assay described above.
MC degranulation. MCs and MC degranulation in skin samples were quan-
tified as previously described (26). Total number of MCs was counted and 
classified as degranulated (more than 10% of the granules exhibiting fusion 
or discharge) or normal in 5 fields under a light microscope with ×400 mag-
nification. The results were expressed as a percentage of MC degranulating 
(number of degranulating MCs/total number of MCs per field).
Statistical analysis. For statistical analysis, the data were expressed as 
mean ± SEM and were analyzed using Student’s t test. A P value of less than 
0.05 was considered significant.
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